IP Library › Granted Patent US 11,911,448
Granted Patent B2
US 11,911,448 · App. 16/535,398 · Granted Feb 27, 2024

Stable liquid thrombin compositions

Inventors: Erez Ilan (Kibbutz Netzer Sereni, IL); Omri Faingold (Rehovot, IL); Sivan Doron (Moshav Arugot, IL)
Assignee: Omrix Biopharmaceuticals Ltd.
A61K38/4833A61K47/02A61K47/10A61K47/42A61P7/04C12Y304/21005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,911,448
App. No.
16/535,398
Granted
Feb 27, 2024
Kind
B2
Abstract

The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.

Claims (8)

1. A hemostatic kit comprising:

a. a container containing a liquid composition of a large-scale and storage-stable sterile preparation comprising thrombin and more than about 60% v/v glycerol; and

b. a container containing gelatin;

wherein the storage-stable sterile preparation is characterized in that the thrombin in the liquid composition retains at least 90% of its original activity after about 2 minutes at a temperature of about 100° C.

2. The hemostatic kit according to claim 1 , wherein the liquid composition comprises about 80% to about 100% v/v glycerol.

3. The hemostatic kit according to claim 1 , wherein the kit further comprises calcium.

4. The hemostatic kit according to claim 1 , wherein the liquid composition further comprises one or more excipients selected from the group consisting of sodium chloride, mannitol, albumin, and sodium acetate.

5. The hemostatic kit according to claim 1 , wherein the liquid composition comprises between about 100 and about 2,000 IU/ml of thrombin.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE 3RD ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 050850 FRAME: 0415. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2021
From: ILAN, EREZ; FAINGOLD, OMRI; DORON, SIVAN
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 055146/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2019
From: ILAN, EREZ; FAINGOLD, OMRI; DORON, SIVIAN
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 050850/0415 →
Priority Claims (1)
IL 261190 · Aug 16, 2018 · national
Continuity (2)
Provisional Application 62764856 · Aug 16, 2018
Related Publication 20200054720A1 · Feb 20, 2020